Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Branko Cuglievan, David McCall, Lindsay Robusto, M. Estela Mireles & Suzanne C. Gettys. (2022) Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia. Expert Opinion on Pharmacotherapy 23:17, pages 1915-1925.
Read now
Read now
J. Parigger, C. M. Zwaan, D. Reinhardt & G. J. L. Kaspers. (2016) Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy 16:2, pages 137-146.
Read now
Read now
Clara Bertuzzi, Stefania Paolini, Giuseppe Visani & Pier Paolo Piccaluga. (2014)
Daunorubicin for the treatment of acute myeloid leukemia. Expert Opinion on Orphan Drugs 2:10, pages 1075-1087.
Read now
Read now
Mascha Binder & Martin Trepel. (2009) Drugs targeting integrins for cancer therapy. Expert Opinion on Drug Discovery 4:3, pages 229-241.
Read now
Read now
Piotr Smolewski, Zbigniew Darzynkiewicz & Tadeusz Robak. (2003) Caspase-mediated Cell Death in Hematological Malignancies: Theoretical Considerations, Methods of Assessment, and Clinical Implications. Leukemia & Lymphoma 44:7, pages 1089-1104.
Read now
Read now
Articles from other publishers (52)
Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu & Jiuda Zhao. (2023) Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis. Cancer Innovation 2:5, pages 346-375.
Crossref
Crossref
Toan D. Nguyen, Brandon M. Bordeau & Joseph P. Balthasar. (2023) Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers 15:3, pages 713.
Crossref
Crossref
Marzieh Ahangarpour, Iman Kavianinia & Margaret A. Brimble. (2023) Thia-Michael addition: the route to promising opportunities for fast and cysteine-specific modification. Organic & Biomolecular Chemistry.
Crossref
Crossref
Shally Rana, Ranjay Shaw, Randhir Kumar, Prasenjit Chakraborty & Sujoy Bandyopadhyay. 2023. Bioconjugated Materials Part 1 Preparation, Characterization and Applications in Therapeutics, Environmental monitoring and Point-of-care diagnostics. Bioconjugated Materials Part 1 Preparation, Characterization and Applications in Therapeutics, Environmental monitoring and Point-of-care diagnostics
43
91
.
Amol D. Gholap, Juhi S. Gupta, Pallavi A. Kamandar, Gauri V. Banchhod & Navnath T. Hatvate. 2023. Bioconjugated Materials Part 2 Applications in Drug Delivery, Vaccine Formulations and Important Conjugates for Cancer Therapy. Bioconjugated Materials Part 2 Applications in Drug Delivery, Vaccine Formulations and Important Conjugates for Cancer Therapy
105
190
.
Sheikdawood Parveen, T. Sathiyapriya, D. Tharani, S. U. Mohammed Riyaz, Rakshi Anuja Dinesh, Jayashree Shanmugam, K. Rajakumar, Dmitry Zherebtsov, Manikandan Dhayalan & Antony Stalin. 2023. Engineered Biomaterials. Engineered Biomaterials
563
578
.
Faiza Javaid, Camilla Pilotti, Carlotta Camilli, David Kallenberg, Calise Bahou, Jack Blackburn, James R. Baker, John Greenwood, Stephen E. Moss & Vijay Chudasama. (2021) Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chemical Biology 2:4, pages 1206-1220.
Crossref
Crossref
Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, Verena I. Gaidzik, Richard F. Schlenk, Peter Paschka, Daniela Weber, Walter Fiedler, Michael W.M. Kühn, Thomas Schroeder, Karin Mayer, Michael Lübbert, Dhanya Ramachandran, Axel Benner, Arnold Ganser, Hartmut Döhner, Michael Heuser, Konstanze Döhner & Felicitas Thol. (2021) Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica 106:11, pages 2986-2989.
Crossref
Crossref
Heiko Konig & Joshua F. Zeidner. (2020) Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development. Current Cancer Drug Targets 20:7, pages 471-472.
Crossref
Crossref
Seok-Beom Yong, Jee Young Chung, Seong Su Kim, Hyung Seok Choi & Yong-Hee Kim. (2020) CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells. Biomaterials 230, pages 119651.
Crossref
Crossref
Yilan Ma, Mingjiong Zhang, Jiayan Wang, Xiaochen Huang, Xingwang Kuai, Xiaojuan Zhu, Yuan Chen, Lizhou Jia, Zhenqing Feng, Qi Tang & Zheng Liu. (2019) High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Frontiers in Oncology 9.
Crossref
Crossref
Gina Keiffer & Neil Palmisiano. (2019) Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients. Current Oncology Reports 21:8.
Crossref
Crossref
Michelle H. Townsend, Gajendra Shrestha, Richard A. Robison & Kim L. O’Neill. (2018) The expansion of targetable biomarkers for CAR T cell therapy. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Etienne Paubelle, Sophie Ducastelle-Leprêtre, Hélène Labussière-Wallet, Franck Emmanuel Nicolini, Fiorenza Barraco, Adriana Plesa, Gilles Salles, Eric Wattel & Xavier Thomas. (2016) Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?. Annals of Hematology 96:3, pages 363-371.
Crossref
Crossref
Stephen S. ChungWilliam S. EngWenhuo HuMona KhalajFrancine E. Garrett-BakelmanMontreh TavakkoliRoss L. LevineMartin CarrollVirginia M. KlimekAri M. MelnickChristopher Y. Park. (2017) CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Science Translational Medicine 9:374.
Crossref
Crossref
Jennifer Davila, Emily Slotkin & Thomas Renaud. (2013) Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments. Pediatric Drugs 16:2, pages 151-168.
Crossref
Crossref
Teng Jiang, Jin-Tai Yu, Nan Hu, Meng-Shan Tan, Xi-Chen Zhu & Lan Tan. (2013) CD33 in Alzheimer's Disease. Molecular Neurobiology 49:1, pages 529-535.
Crossref
Crossref
Sohsuke Meshitsuka, Mitsuo Hori, Shoichi Mitsuhashi, Yasushi Okoshi & Hiroshi Kojima. (2014) Reinduction Chemotherapy with Gemtuzumab Ozogamicin and Intermediate/High-Dose Cytarabine: A Single-Center Experience. Open Journal of Blood Diseases 04:01, pages 1-8.
Crossref
Crossref
Hiroko Tsunemine & Takayuki Takahashi. (2013) Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia. Health 05:05, pages 8-16.
Crossref
Crossref
Dana Litvak-Greenfeld & Itai Benhar. (2012) Risks and untoward toxicities of antibody-based immunoconjugates. Advanced Drug Delivery Reviews 64:15, pages 1782-1799.
Crossref
Crossref
Ursula Creutzig. 2013. Childhood Leukemias. Childhood Leukemias
421
428
.
Stephen C. Alley, Simone Jeger, Robert P. Lyon, Django Sussman & Peter D. Senter. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
289
323
.
Maciej Bogdan Maniecki, Henrik Hasle, Knud Bendix & Holger Jon Møller. (2011) Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?. Leukemia Research 35:6, pages e84-e86.
Crossref
Crossref
Richard M. Stone, Barry Moser, Ben Sanford, Philip Schulman, Jonathan E. Kolitz, Steven Allen, Wendy Stock, Ilene Galinsky, Ravi Vij, Guido Marcucci, David Hurd & Richard A. Larson. (2011) High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leukemia Research 35:3, pages 329-333.
Crossref
Crossref
Camille N. Abboud. 2011. Adult Acute Lymphocytic Leukemia. Adult Acute Lymphocytic Leukemia
257
275
.
Markus Kügler, Christoph Stein, Christian Kellner, Kristin Mentz, Domenica Saul, Michael Schwenkert, Ingo Schubert, Heiko Singer, Fuat Oduncu, Bernhard Stockmeyer, Andreas Mackensen & Georg H. Fey. (2010) A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. British Journal of Haematology 150:5, pages 574-586.
Crossref
Crossref
Heiko Singer, Christian Kellner, Harald Lanig, Michael Aigner, Bernhard Stockmeyer, Fuat Oduncu, Michael Schwemmlein, Christoph Stein, Kristin Mentz, Andreas Mackensen & Georg H. Fey. (2010) Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16. Journal of Immunotherapy 33:6, pages 599-608.
Crossref
Crossref
Iris Middeldorf, Oliver Galm, Rainhardt Osieka, Edgar Jost, James G. Herman & Stefan Wilop. (2010) Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). American Journal of Hematology 85:7, pages 477-481.
Crossref
Crossref
Christoph Stein, Christian Kellner, Markus Kügler, Nina Reiff, Kristin Mentz, Michael Schwenkert, Bernhard Stockmeyer, Andreas Mackensen & Georg H. Fey. (2010) Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. British Journal of Haematology 148:6, pages 879-889.
Crossref
Crossref
Huguette Albrecht. 2010. Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy, and Prognosis
135
152
.
Iqbal Grewal. 2009. Emerging Protein Biotherapeutics. Emerging Protein Biotherapeutics.
Peter Senter & Dennis Benjamin. 2009. Emerging Protein Biotherapeutics. Emerging Protein Biotherapeutics.
Peter D Senter. (2009) Potent antibody drug conjugates for cancer therapy. Current Opinion in Chemical Biology 13:3, pages 235-244.
Crossref
Crossref
J K Lamba, S Pounds, X Cao, J R Downing, D Campana, R C Ribeiro, C-H Pui & J E Rubnitz. (2008) Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia 23:2, pages 402-404.
Crossref
Crossref
Jennifer J. Clark, Jason N. Berman & A. Thomas Look. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
331
402
.
Stephan Von Gunten & Bruce S. Bochner. (2008) Basic and Clinical Immunology of Siglecs. Annals of the New York Academy of Sciences 1143:1, pages 61-82.
Crossref
Crossref
Maciej Bogdan ManieckiHenrik HasleLennart Friis-HansenBirgitte Lausen, Ove Juul NielsenKnud Bendix, Søren Kragh Moestrup & Holger Jon Møller. (2008) Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood 112:4, pages 1510-1514.
Crossref
Crossref
Deborah Mulford. (2008) Antibody Therapy for Acute Myeloid Leukemia. Seminars in Hematology 45:2, pages 104-109.
Crossref
Crossref
Alejandro D Ricart & Anthony W Tolcher. (2007) Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. Nature Clinical Practice Oncology 4:4, pages 245-255.
Crossref
Crossref
Richard M. Stone. (2007) Novel therapeutic agents in acute myeloid leukemia. Experimental Hematology 35:4, pages 163-166.
Crossref
Crossref
S Jäger, A Jahnke, T Wilmes, S Adebahr, F-N Vögtle, E deLima-Hahn, D Pfeifer, T Berg, M Lübbert & M Trepel. (2007) Leukemia targeting ligands isolated from phage display peptide libraries. Leukemia 21:3, pages 411-420.
Crossref
Crossref
Richard M. Stone. 2007. Acute Myelogenous Leukemia. Acute Myelogenous Leukemia
373
384
.
Michael Schwemmlein, Matthias Peipp, Karin Barbin, Domenica Saul, Bernhard Stockmeyer, Roland Repp, Josef Birkmann, Fuat Oduncu, Bertold Emmerich & Georg H. Fey. (2006) A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. British Journal of Haematology 133:2, pages 141-151.
Crossref
Crossref
Jerome E. Tanner. (2005) Designing antibodies for oncology. Cancer and Metastasis Reviews 24:4, pages 585-598.
Crossref
Crossref
Michael Z. Lin, Michael A. Teitell & Gary J. Schiller. (2005) The Evolution of Antibodies into Versatile Tumor-Targeting Agents. Clinical Cancer Research 11:1, pages 129-138.
Crossref
Crossref
Richard M. Schultz. 2005. Advances in Targeted Cancer Therapy. Advances in Targeted Cancer Therapy
1
17
.
Peter Ettmayer, Gordon L. Amidon, Bernd Clement & Bernard Testa. (2004) Lessons Learned from Marketed and Investigational Prodrugs. Journal of Medicinal Chemistry 47:10, pages 2393-2404.
Crossref
Crossref
V H J van der Velden, A Hochhaus, G Cazzaniga, T Szczepanski, J Gabert & J J M van Dongen. (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17:6, pages 1013-1034.
Crossref
Crossref
C. Rössig, D. Dilloo & H. Jürgens. (2003) Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter. Monatsschrift Kinderheilkunde 151:6, pages 646-653.
Crossref
Crossref
Liping Feng, Dalip Kumar & Sean M. Kerwin. (2003) An Extremely Facile Aza-Bergman Rearrangement of Sterically Unencumbered Acyclic 3-Aza-3-ene-1,5-diynes. The Journal of Organic Chemistry 68:6, pages 2234-2242.
Crossref
Crossref
. (2002) Current Awareness. Pharmacoepidemiology and Drug Safety 11:4, pages 345-360.
Crossref
Crossref
RA Larson. (2001) New agents for induction and postremission therapy of acute myeloid leukemia. Leukemia 15:4, pages 675-676.
Crossref
Crossref